HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fibrates in the secondary prevention of cardiovascular disease (infarction and stroke). Results of a systematic review and meta-analysis of the Cochrane collaboration.

Abstract
Fibrates are a group of drugs that are known mainly for reducing triglycerides, increasing high density lipoproteins (HDL), and reducing the fraction of small, dense LDL particles. The results of a Cochrane Collaboration study have recently been published on their efficacy and safety in the secondary prevention of severe cardiovascular accidents, including coronary and cerebrovascular disease. The study included randomised clinical trials in which the fibrate was compared with placebo or with no treatment. Clinical trials comparing two different fibrates were excluded. The clinical trials evaluated included a total of 16,112 patients (13 trials). The meta-analysis (including all the trials with fibrates) showed evidence of a protective effect of the fibrates compared with placebo as regards a compound objective of non-fatal stroke, non-fatal myocardial infarction, and death of cardiovascular origin (hazard ration of 0.88, with a 95% confidence interval of 0.83 to 0.94; in 16,064 individuals included in 12 studies). Thus, the results showed, with a moderate level of evidence, that fibrates could be effective in secondary prevention considering a compound objective of non-fatal stroke, non-fatal myocardial infarction, and death of cardiovascular origin.
AuthorsJesus Millan, Xavier Pintó, Angel Brea, Mariano Blasco, Antonio Hernández-Mijares, Juan Ascaso, Angel Diaz, Teresa Mantilla, Juan Pedro-Botet
JournalClinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis (Clin Investig Arterioscler) 2018 Jan - Feb Vol. 30 Issue 1 Pg. 30-35 ISSN: 1578-1879 [Electronic] Spain
Vernacular TitleLos fibratos en la prevención secundaria de la enfermedad cardiovascular (infarto e ictus). Resultados de una revisión sistemática y metaanálisis de la colaboración Cochrane.
PMID29395493 (Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
CopyrightCopyright © 2017. Publicado por Elsevier España, S.L.U.
Chemical References
  • Fibric Acids
  • Hypolipidemic Agents
Topics
  • Cardiovascular Diseases (etiology, prevention & control)
  • Fibric Acids (adverse effects, therapeutic use)
  • Humans
  • Hypolipidemic Agents (adverse effects, therapeutic use)
  • Myocardial Infarction (etiology, prevention & control)
  • Randomized Controlled Trials as Topic
  • Secondary Prevention (methods)
  • Stroke (etiology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: